Citi analyst Yigal Nochomovitz has maintained their bullish stance on ZLAB stock, giving a Buy rating yesterday.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Yigal Nochomovitz has given his Buy rating due to a combination of factors related to Zai Lab’s recent clinical trial outcomes and future potential. The announcement of the successful interim results from the Phase 3 FORTITUDE-101 trial, which led to the early termination of the study due to significant efficacy, is a crucial factor. This outcome suggests a promising future for Zai Lab’s product in treating FGFR2b+ gastric cancer, despite some concerns about ocular adverse events that need further clarification.
Additionally, Nochomovitz maintains a positive outlook on the probability of success for bemarituzumab, with a 70% chance of success in the targeted cancer treatment. The anticipation of further data from another Phase 3 trial, FORTITUDE-102, which is expected to report in the second half of 2025, also supports the Buy rating. The expected share price return of 87.2% further underscores the positive sentiment and potential for significant investment returns.
According to TipRanks, Nochomovitz is a 4-star analyst with an average return of 3.4% and a 38.98% success rate. Nochomovitz covers the Healthcare sector, focusing on stocks such as Summit Therapeutics, Travere Therapeutics, and Arcturus Therapeutics.